title: The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation.
abstract: Ketorolac tromethamine solution 0.5% (1 drop 3 times daily) was more effective than the placebo vehicle solution in suppressing postoperative anterior ocular inflammation after extracapsular cataract extraction (ECCE) and intraocular lens (IOL) implantation in this multicenter, double-masked, randomized study. Four of 60 ketorolac-treated patients compared with 25 of 58 placebo-treated patients required supplemental corticosteroid therapy to suppress inflammation in the postoperative period which was statistically significant (P less than 0.001). Even though these supplemental steroid-treated patients were kept in the analysis, the placebo-treated group showed more evidence of anterior ocular inflammation as measured by anterior segment fluorophotometry. This was consistent with slit-lamp observations of increased anterior ocular inflammation. This study supported previous studies that suggested ketorolac tromethamine ophthalmic solution 0.5% was effective and safe as a nonsteroidal anti-inflammatory agent for topical use after ECCE and IOL implantation.
authors.affiliation: Department of Ophthalmology, University of California, San Francisco Medical Center.
authors.forename: A J
authors.initials: AJ
authors.lastname: Flach
authors.forename: C J
authors.initials: CJ
authors.lastname: Lavelle
authors.forename: K W
authors.initials: KW
authors.lastname: Olander
authors.forename: J A
authors.initials: JA
authors.lastname: Retzlaff
authors.forename: L W
authors.initials: LW
authors.lastname: Sorenson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000869:Anterior Eye Segment; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002387:Cataract Extraction / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D009877:Endophthalmitis / Q000517:prevention & control; D005260:Female; D006801:Humans; D020911:Ketorolac Tromethamine; D007910:Lenses, Intraocular / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010919:Placebos; D011183:Postoperative Complications / Q000517:prevention & control*; D011758:Pyrroles / Q000627:therapeutic use*; D014046:Tolmetin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014325:Tromethamine / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D010919:Placebos; D011758:Pyrroles; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin